Patent ID: 8460702
Filing Date: 2013-06-11
Classification: A61K,A61P

Abstract:
1. A sustained release pharmaceutical composition consisting of (I) a matrix form comprising: (a) 0.001-60% w/w of liothyronine or the sodium salt of liothyronine; (b) 10-60% w/w of microcrystalline cellulose; (c) 10-60% w/w of a diluent; (d) 5-25% w/w of a glidant; and (e) one or more of ethylcellulose having an ethoxyl substitution of from 47 to 51% and a viscosity (5% solution in 80/20 toluene/ethanol) of from 5 to 40 cps, stearic acid and a salt of stearic acid, in an amount such that the total weight of component (e) is from 10 to 60% w/w; and (II) an optional enteric coating, coating the matrix.